Nigeria gets nod to host African Energy Bank


Nigeria has been granted the hosting right for the African Energy Bank (AEB), after beating Ghana, Benin Republic, Algeria, South Africa and Cote D’Ivoire in a keenly contested bidding.

Sen. Heineken Lokpobiri, the Minister of State, Petroleum Resources (Oil), told newsmen in Abuja on Thursday, that the award of hosting right for the bank highlighted Nigeria’s robust energy sector.

He said, ‘the award of the hosting right also highlights the country ‘s strategic vision for Africa’s energy future.’

Lokpobiri expressed gratitude to President Bola Tinubu for the support extended during the course of the bidding.

He also thanked the Council of Ministers of the African Petroleum Producers Organisation (APPO) for the confidence in Nigeria’s capability.

The minister highlighted the collaborative spirit of the APPO members and their shared vision for a united, energy-secured Africa.

He emphasised that ‘this decision reflects our collective ambition to create African solutions to Africa’s energy challenges.

‘Th
e African Energy Bank will be instrumental to providing the necessary financial backbone for energy projects that will drive growth and development across the continent.

‘The decision is a significant step for the continent’s energy sector and underscores Nigeria’s pivotal role in Africa’s energy landscape.’

The minister assured Nigerians and Africans at large that the establishment of the African Energy Bank would mark a transformative era in meeting energy needs.

He said that the initiative aligned with the broader objectives of African Union’s Agenda 2063, aiming for a prosperous and self-sustaining Africa.

‘We are committed to ensuring that the bank did not only move Nigeria forward, but becomes a beacon of progress for the entire continent.

‘Our goal is to foster sustainable energy solutions that are both innovative and inclusive.’

The News Agency of Nigeria (NAN) reports that the bank is expected to facilitate access to funding for energy projects, thereby catalysing economic growth and enhancing
energy security.

Source: News Agency of Nigeria

Recertification: NCAA suspends 10 private jet operations


The Nigeria Civil Aviation Authority (NCAA), has suspended ten private jet operations over failure to begin recertification process.

This is contained in a statement by Mr Michael Achimugu, Director, Public Affairs and Consumer Protection on Friday in Abuja.

The agency said the Nigeria Civil Aviation Regulations 2023 Part 18.3.4 forbids holders of Permit for Non Commercial Flights (PNCF) from using their aircraft for carriage of passengers, cargo or mail for hire or rewards (commercial operation or charter services)

‘As a result of flagrant disregard of this rule, the NCAA had earlier directed all holders of PNCF to undergo re-evaluation which should have been concluded by the April 19, 2024.

‘To this end, the NCAA has suspended the PNCF of Azikel Dredging Nigeria Ltd, Bli-Aviation Safety Services, Ferry Aviation Developments Ltd and Matrix Energy Ltd.

‘Also Marrietta Management Services Ltd, Worldwide Skypaths Services, Mattini Airline Services Ltd, Aero Lead Ltd, Sky Bird Air Ltd and Ezuma Jets Ltd.


The public is hereby notified that it is illegal to engage PNCF holders for commercial purposes. The NCAA will not hesitate to initiate enforcement actions against any PNCF holder found guilty of illegal operations’.

The agency said that its officials had been deployed to General Aviation Terminals (GAT) and private wings of the airports to monitor activities of the PNCF holders.

Source: News Agency of Nigeria

Tinubu mandates Presidential Economic Coordination Council to strengthen economy


President Bola Tinubu on Thursday inaugurated the Presidential Economic Coordination Council (PECC), mandating it to strengthen the economy.

He also inaugurated the Economic Stabilisation Programme to ensure food security, improved power supply, enhanced social welfare and healthcare, increased energy production, and overall economic transformation.

Speaking during the inaugural of the 31-member Council at the Council Chambers in Abuja, Tinubu, who chairs the Council, underscored the need for innovative solutions to the country’s economic challenges.

He noted the importance of public-private partnerships in driving economic reforms.

‘We have the challenge of energy security in Nigeria. We need to work together to improve our oil and gas sector, and we must also increase electricity generation and distribution throughout the country.

‘We are determined to do that with your cooperation, collaboration, and recommendations.

‘As a nation, it is so shameful that we are still generating 4.5GW of electricity.

‘We must increase our oil production to 2 million barrels per day within the next few months and we are determined to remove all entry barriers to investments in the energy sector while enhancing competitiveness.’

He announced measures, which would run concurrently with the National Construction and Household Support Programme, to stabilise the economy, enhance job creation, and foster economic security.

The News Agency of Nigeria (NAN) reports that the measures under the Economic Stabilisation Programme include Energy Security, which includes power, oil and gas, aims to increase on-grid electricity to be delivered to homes and businesses from about 4.5 gigawatts to 6 gigawatts in six months.

It also aims at increasing oil production to two million barrels per day within the next 12 months; and remove barriers to entry for investments into the sector to enhance competitiveness.

The programme includes Agriculture and Food Security, which aims at increase staple crops grown by small-holder farmers from 127
million metric tonnes in 2023 to 135 million metric tonnes this year.

It will bolster production by partnering larger-scale commercial farmers and support qualified farmers with satellite imagery for land use planning, crop rotation, and monitoring of agricultural expansion.

Another aspect of the plan is Health and Social Welfare under which the Federal Government hopes to make essential medicines available at lower cost for 80-90 million Nigerians.

It will also expand healthcare insurance coverage for one million vulnerable people via a Vulnerable Group Fund in collaboration with state governments.

It will redeploy 20,000 healthcare workers to provide services to 10-12 million patients in areas where they are most urgently needed and power up 4,800 primary healthcare centres (PHCs), second tier, and third tier hospitals using renewable energy sources.

Under the Economic Stabilisation Programme, Tinubu said some fiscal measures had been introduced to improve access to finance for the housing sector, MSME
s, and the manufacturing sector are.

The measures include support for new and existing youth-owned enterprises across all 36 states of the Federation, creating 7,400 MSMEs within the next 6-12 months.

There is also MSME support, a N650 billion facility that will provide lower-cost short-term facilities to youth-owned businesses, manufacturers and MSMEs across various industries; food processing, pharmaceutical, agriculture, and wholesale and retail trade.

‘This financing will be based on their current and future receivables, company rating, and market demand for products.

‘A Manufacturing Stabilisation Fund will rejuvenate up to two hundred and fifty companies and deliver lower cost (9.0 per cent -11.0 per cent) long-term facilities to large, medium-scale, and light manufacturers that produce finished goods for domestic and export markets.

‘Sub-national Matching Fund: A Grow Nigeria Development Fund consisting of a single-digit interest rate loan portfolio with the Bank of Industry and a matching fund ag
reement with sub-national governments to grow MSMEs,’ said the President.

He stated that the Bank of Industry’s Rural Development Programme would be expanded to support rural economies by developing 300 new MSMEs for each state, including the Federal Capital Territory, Abuja, resulting in 11,100 new rural-based MSMEs across the Federation.

‘Mortgage Finance Acceleration Facility: A facility that delivers affordable housing for all segments impacted by the cost-of-living challenge.

‘This will support the construction of an additional 25,000 housing units.

‘These fiscal measures will improve access to finance for MSMEs and, in the process, create 4.7 million direct and indirect jobs over a six to 12-month period,’ said Tinubu.

Emphasising the significance of the task ahead, Vice-President Kashim Shettima, who is the Vice-Chairman of the Council, stated that President Tinubu was committed to proffering solutions to the nation’s economic challenges and not apportioning blame.

‘I want to emphasise that when
there is a will, there is always a way, and the President does not believe in apportioning blame. He believes in preparing solutions,’ Shettima said.

Mr Wale Edun, the Coordinating Minister of the Economy and Minister of Finance, made a presentation on the highlights of the Accelerated Stabilisation and Advancement Plan earlier submitted to the President.

The plan details economic issues to be resolved in 2024 by sub-committees in the key sectors of agriculture and food security, energy (oil, gas, power), health and social welfare, and business support.

Other members of the council include the Senate President, the Speaker of the House of Representatives, Chairman of the Nigeria Governors Forum, twelve ministers, and the Governor of the Central Bank of Nigeria.

Members from the Organised Private sector include: Alhaji Aliko Dangote, Mr Tony Elumelu, Alhaji Abdul Samad Rabiu, Ms Amina Maina, Mr Segun Ajayi-Kadir, Dr Funke Opeke, Dr Doyin Salami among others. (NAN) (www.nannews.ng)

Source: News Agency of
Nigeria

CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe

MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) — Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the first gene therapy administered as a treatment in a real-world setting for hemophilia B in Europe.

HEMGENIX® is the first one-time gene therapy approved in Europe for the treatment of adults with severe and moderately severe hemophilia B, an inherited bleeding disorder caused by the lack of Factor IX (a protein needed to produce blood clots to stop bleeding). It is used in adults without a history of Factor IX inhibitors.1

Following European Commission approval, HEMGENIX® was the first ever therapy to be granted Direct Access in France2, thus enabling the first patients to be treated in Europe outside of the clinical program.

Though effective, current therapies can be time intensive and require regular treatment that can have a substantial impact on a patient’s daily life.3 HEMGENIX® offers a one-time treatment, allowing people living with hemophilia B to produce their own Factor IX, which can lower the risk of bleeding.4

“Only a few decades ago, gene therapy for hemophilia was a distant concept, which has now become reality. Accordingly, the first two patients treated with HEMGENIX® since receiving European approval is a major accomplishment and a testament to the joint commitment of the hemophilia B community, as well as the access and reimbursement authorities, in bringing innovative therapies to patients,” said Dr Lutz Bonacker SVP and General Manager, CSL Behring Commercial Operations Europe. “This milestone has been made possible by the innovative Direct Access scheme adopted in France, allowing patients to benefit from early access to pioneering treatments. We are encouraged to see increasing access to gene therapies in European countries and are fully committed to ensuring that access to potentially life-changing treatment continues.”

HEMGENIX® was granted conditional marketing authorisation by the European Commission (EC) for the European Union and European Economic Area in February 2023, following approval from the U.S. Food and Drug Administration (FDA) in November 2022. It has also been approved by Health Canada, the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA), Switzerland’s Swissmedic and Australia’s Therapeutic Goods Administration (TGA).

The multi-year clinical development of HEMGENIX® was led by uniQure and sponsorship of the clinical trials transitioned to CSL after it licensed global rights to commercialise the treatment.

About Hemophilia B

Hemophilia B is a life-threatening rare disease. People with the condition are particularly vulnerable to bleeds in their joints, muscles, and internal organs, leading to pain, swelling, and joint damage. Current treatments for moderate to severe hemophilia B include life-long prophylactic infusions of factor IX to temporarily replace or supplement low levels of the blood-clotting factor.

About HEMGENIX®

HEMGENIX® is a gene therapy that reduces the rate of abnormal bleeding in eligible people with hemophilia B by enabling the body to continuously produce factor IX, the deficient protein in hemophilia B. It uses AAV5, a non-infectious viral vector, called an adeno-associated virus (AAV). The AAV5 vector carries the Padua gene variant of Factor IX (FIX-Padua) to the target cells in the liver, generating factor IX proteins that are 5x-8x more active than normal. These genetic instructions remain in the target cells, but generally do not become a part of a person’s own DNA. Once delivered, the new genetic instructions allow the cellular machinery to produce stable levels of factor IX.

About the Pivotal HOPE-B Trial

The pivotal Phase III HOPE-B trial is an ongoing, multinational, open-label, single-arm study to evaluate the safety and efficacy of HEMGENIX®. Fifty-four adult hemophilia B patients classified as having moderately severe to severe hemophilia B and requiring prophylactic factor IX replacement therapy were enrolled in a prospective, six-month or longer observational period during which time they continued to use their current standard of care therapy to establish a baseline Annual Bleeding Rate (ABR). After the six-month lead-in period, patients received a single intravenous administration of HEMGENIX® at the 2×10^13 gc/kg dose. Patients were not excluded from the trial based on pre-existing neutralizing antibodies (NAbs) to AAV5.

A total of 54 patients received a single dose of HEMGENIX® in the pivotal trial, with 52 patients completing at least three years of follow-up. The primary endpoint in the pivotal HOPE-B study was ABR 52 weeks after achievement of stable factor IX expression (months 7 to 18) compared with the six-month lead-in period. For this endpoint, ABR was measured from month seven to month 18 after infusion, ensuring the observation period represented a steady-state factor IX transgene expression. Secondary endpoints included assessment of factor IX activity.

No serious treatment-related adverse reactions were reported. One death resulting from urosepsis and cardiogenic shock in a 77-year-old patient at 65 weeks following dosing was considered unrelated to treatment by investigators and the company sponsor. A serious adverse event of hepatocellular carcinoma was determined to be unrelated to treatment with HEMGENIX® by independent molecular tumour characterization and vector integration analysis. No inhibitors to factor IX were reported.

Long-term three-year data presented at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) 2024 continue to reinforce the potential long-lasting efficacy and safety of HEMGENIX® and the ongoing benefit of this treatment for people living with hemophilia B.

About CSL
CSL (ASX:CSL; USOTC:CSLLY) is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSL.com/Vita. For more information about CSL, visit CSL.com.

Media Contacts
Stephanie Fuchs
Mobile: +49 151 584 388 60
Email: Stephanie.Fuchs@cslbehring.com

References


1 European Medicines Agency. First Gene therapy to treat haemophilia B. Available at: https://www.ema.europa.eu/en/news/first-gene-therapy-treat-haemophilia-b. [Accessed May 2024].
2 Republique Française. Légifrance: Article 62 of Law No. 2021-1754. Available at: https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000048551003 [Accessed May 2024].
3 Leebeek, F & Miesbach, W. (2021) Gene therapy for haemophilia: a review on clinical benefit, limitations, and remaining issues. Blood. Vol 138, Issue 11. pp923-931.
4 Coppens M et al. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial. The Lancet Haematology 2024; 11(4):E265-E275.

GlobeNewswire Distribution ID 1000969961

36th Regular Session of HPR Underway in Presence of PM Abiy


Addis Ababa: Ethiopia’s House of Peoples Representatives (HPR) is holding its 36th regular session in the presence of Prime Minister Abiy Ahmed.

The Prime Minister will address questions from members of the House in addition to his explanation about the federal government’s draft budget proposed by Council of Ministers last month.

Recall the Council of Ministers has proposed a close to 1 trillion Birr federal budget for the upcoming fiscal year.

The budget is prepared in tune with the Ten-year Prospective Development Plan and the 2017-2021 medium-term macroeconomic and fiscal frameworks of the country by considering the government’s financial capacity and expected revenues as well as expenses.

According to Ministry of Finance, the proposed budget prioritizes domestic funding sources and invests in productive sectors to boost productivity and economic output.

Poverty reduction and sustainable development are central to the budget plan, whose 92 percent of the source is expected to come from tax collection
.

The House of Peoples Representatives in its session today is also expected to approve this budget.

Diplomats of various countries and representatives of multilateral organizations based in Addis Ababa religious leaders and other invited guests are in attendance.

Source: Ethiopian News Agency

36th Regular Session of HPR Underway in Presence of PM Abiy


Addis Ababa: Ethiopia’s House of Peoples Representatives (HPR) is holding its 36th regular session in the presence of Prime Minister Abiy Ahmed.

The Prime Minister will address questions from members of the House in addition to his explanation about the federal government’s draft budget proposed by Council of Ministers last month.

Recall the Council of Ministers has proposed a close to 1 trillion Birr federal budget for the upcoming fiscal year.

The budget is prepared in tune with the Ten-year Prospective Development Plan and the 2017-2021 medium-term macroeconomic and fiscal frameworks of the country by considering the government’s financial capacity and expected revenues as well as expenses.

According to Ministry of Finance, the proposed budget prioritizes domestic funding sources and invests in productive sectors to boost productivity and economic output.

Poverty reduction and sustainable development are central to the budget plan, whose 92 percent of the source is expected to come from tax collection
.

The House of Peoples Representatives in its session today is also expected to approve this budget.

Diplomats of various countries and representatives of multilateral organizations based in Addis Ababa religious leaders and other invited guests are in attendance.

Source: Ethiopian News Agency